orchid-cb-receives-brutal-treatment-in-the-secondary-market

Orchid CB receives brutal treatment in the secondary market

A hefty increase in the deal size and concern about the use of proceeds push the bond price sharply below par.
The convertible bonds issued by Indian drug maker Orchid Chemicals Pharmaceuticals on Monday have been the talk of the CB community this week û and not for reasons that the company would likely want to remember.

Still, the ordeal has highlighted the importance of proper communication, not only by the banks involved in the transaction but by issuers too as they need to make sure investors are fully aware of their intentions.

OrchidÆs zero-coupon CB appears to have failed on both these accounts.

The mayhem started when the share price dropped 9.8% on the day after the issue. This led to confusion among the bond holders, who promptly started to offload the CBs pushing their...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222